HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024

HOOKIPA Pharma Inc.

Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.
Pro-forma cash of $156.9M (Dec 31, 2021) reflects $35M Gilead equity, $15M fee, and $70M follow-on proceeds.
Gilead HIV program advanced, triggering $54M commitment; $4M milestone, $15M fee, $35M equity at premium.
HB-200 Phase 2 combo with pembrolizumab in HNSCC dosed Jan 2022; initial data expected H2 2022.
Klaus Orlinger promoted to CSO; executive team accepted 50% of 2021 bonus in options at $3/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.